Form 4: Nurix Therapeutics Director Receives Stock Option Grant

Director Julia P. Gregory was granted 31,250 stock options in Nurix Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Julia P. Gregory received a grant of 31,250 stock options for Nurix Therapeutics, Inc. (NRIX) common stock.
• The options have an exercise price of $15.86 per share.
• The grant is scheduled to vest in full on the earlier of the next annual stockholder meeting or May 15, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $15.86 exercise price.

Future Outlook

The options vest in one year, indicating a standard retention and incentive structure for board members.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain experienced board members, aligning their compensation with the company's long-term clinical and commercial success.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.
• The use of time-based vesting is standard for board-level equity awards.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of the 31,250 options on or before May 15, 2027.

Key Dates

Keywords

Nurix Therapeutics, NRIX, Director Compensation, Stock Options, Insider Transaction, Equity Grant